Table 3.

Initial anti-anxiety medication class in children with diagnosed anxiety beginning anti-anxiety pharmacotherapy

	Primary analysis: Full cohort (N=84,500)		Anxiety diagnosis same day as initial anti- anxiety prescription (N=47,973)		2+ Anxiety diagnoses, no recent comorbid psychiatric diagnosisa (N=20,249)
	No.	% (95% CI)	No.	% (95% CI)	No.	% (95% CI)
SSRI alone	53,009	63% (62–63)	32,044	67% (66–67)	13,492	67% (66–67)
SSRI+another anti-anxiety medicationb	5,863	7% (7–7)	3,664	8% (7–8)	1,147	6% (5–6)
SSRI+benzodiazepine	2,528	3%	1,890	4%	652	3%
SSRI+other antidepressant	926	1%	475	1%	113	1%
SSRI+atypical antipsychotic	894	1%	299	1%	104	1%
SSRI+hydroxyzine	761	1%	511	1%	132	1%
Non-SSRI anti-anxiety medication	25,628	30% (30–31)	12,265	26% (25–26)	5,610	28% (27–28)
Benzodiazepine	7,125	8%	4,038	8%	1,735	9%
Hydroxyzine	3,244	4%	1,937	4%	750	4%
Other antidepressant	2,987	4%	1,051	2%	658	3%
Other anti-anxietyc	2,967	4%	1,090	2%	519	3%
Atypical antipsychotic	2,264	3%	732	2%	343	2%
Bupropion	1,251	1%	592	1%	211	1%
Buspirone	1,226	1%	876	2%	253	1%
TCA	1,157	1%	497	1%	382	2%
Anticonvulsant	988	1%	289	1%	294	1%
SNRI	761	1%	345	1%	165	1%
Beta-blocker	705	1%	391	1%	176	1%
Non-SSRI + Non-SSRI	953	1%	427	1%	124	1%
	84,500	100%	47,973	100%	20,249	100%

^aAt least two anxiety diagnoses in the prior year and no comorbid psychiatric diagnosis in the 30 days before anti-anxiety medication initiation

^bPrimary analysis: SSRI+other anxiety (n=355), SSRI+buspirone (n=133), SSRI+beta-blocker (n=110), SSRI+anticonvulsant (n=83), SSRI+TCA (n=55), SSRI+bupropion (n=17), SSRI+SNRI (not reported due to small sample)

^c98% of prescriptions were clonidine or guanfacine